Skip to main content
. 2020 May 4;31(3):235–240. doi: 10.1007/s13337-020-00592-0

Table 1.

Summary of studies describing the treatment of different genotypes of hepatitis C virus

Genotypes Treatment SVR (%) Duration (weeks) SVR with DAAs (%) References
1 Peg+IFN/Ribavirin 90 48 97 [32]
2 Peg+IFN/Ribavirin 76 48 97 [30]
3 Peg+IFN/Ribavirin 56 48 73 [24]
4 Peg+IFN/Ribavirin 70 48 95 [13]
5 Peg+IFN/Ribavirin 67 48 Unknown [4]
6 Peg+IFN/Ribavirin 75 48 Unknown [15]